摘要
目的 探讨肺癌患者血清 s Apo- 1/Fas测定的临床价值。方法 采用酶联免疫吸附试验 (EL ISA )法检测 30例肺癌患者化疗前后血清 s Apo- 1/Fas水平 ,分析其临床意义。结果 血清 s Apo- 1/Fas水平与病理类型无关 ,受临床分期的影响 ,进展期显著高于早期患者 (P<0 .0 5 ) ,除 + 期外 ,各期化疗前后血清 s Apo- 1/Fas比较差异有显著性 (P<0 .0 5 ) ,化疗前血清 s Apo- 1/Fas升高的小细胞肺癌患者疗效较好。治疗后有效、病情稳定的患者 ,血清 s Apo- 1/Fas水平下降至正常或接近正常。结论 肺癌患者血清 s Apo- 1/Fas水平与患者病情轻重有关 ,是一项判断病情和疗效的指标。
Objective To assess the value of detecting serum sApo-1/Fas of patients with lung cancer.Methods By using ELISA,sApo-1/Fas was detected in patients with lung cancer before and after chemotherapy.Results Serum levels of sApo-1/Fas did not correlate with pathologic types.The more advanced the clinicopathologic stage of malignant tumor,the higher serum levels of sApo-1/Fas (P<0.05).Except for stage Ⅰ and Ⅱ,significant differences were found in serum levels of sApo-1/Fas between before and after chemotherapies in other stages (P<0.05).Patients with small cell lung cancer with sApo-1/Fas higher before chemotherapy were eutherapeutic.The serum levels of sApo-1/Fas would decrease to normal or approach to normal if the remedy to patients was effectual and patients′ conditions were stable.Conclusion The serum level of sApo-1/Fas in patients with lung cancer was related with seriousness of disease,it may become a useful marker in the evaluation of nosography and effectiveness.
出处
《山西医药杂志》
CAS
2004年第8期640-642,共3页
Shanxi Medical Journal
基金
太原市卫生系统科研发展扶持基金项目
